Targeted Literature Review (TLR) of the Economic Burden and Cost-Effectiveness of Treatments for Advanced Non-Small Cell Lung Cancer (ANSCLC)

Author(s)

McGovern A1, Rai P2, Fountain D3, Petrie JL3, Brown R3
1Eisai Inc., Nutley, NJ, USA, 2Merck & Co., Inc., Kenilworth, NJ, USA, 3PHMR Ltd, London, UK

OBJECTIVES:

With the availability of new treatment options for aNSCLC (ie; immunotherapies [ICIs]), there has been an increase in healthcare costs despite dramatically improved survival outcomes. A TLR was performed to evaluate the economic burden and cost-effectiveness of aNSCLC treatments and identify evidence gaps.

METHODS:

Literature published between January 2016 - January 2021 was identified by searching MEDLINE, Embase, and NHS Economic Evaluations Databases. Publications evaluating adult patients (18 years) with treatment-naïve aNSCLC (stage IIIB/C and stage IV) not eligible for targeted therapy were included.

RESULTS:

After screening 5,464 records, 20 relevant publications were included (7 healthcare cost/utilization; 13 cost-effectiveness analyses). In the US, costs pre-approval were higher than post-approval of ICIs for total direct healthcare (1L: $87,890±$96,925 vs. $80,206±$69,033; p=0.011), hospitalization (1L: $22,296±$69,506 vs. $14,406±$20,981; p=0.009), and emergency department (ED) visits (1L: $30,236±$44,805 vs. $20,432±$22,600; p<0.001). The costs associated with stage of disease were lower for early stage disease; however, costs were comparable for aNSCLC. Mean wage loss for patients diagnosed with aNSCLC were significantly higher for stage IV disease compared to stage IIIB (€2282 vs €499; p = 0.0135) and the financial burden was most impactful on patients and caregivers. Cost-effectiveness of ICIs alone or in combination varied by country and did not change significantly based on PD-L1 expression.

CONCLUSIONS:

Despite the increased cost of ICIs compared to other available treatments, the lower costs of hospitalization resulted in a favorable effect on the total cost of care for aNSCLC. Overall, cost-effectiveness studies reported that ICIs were cost effective. Indirect cost data indicate that the financial burden of aNSCLC on patients and caregivers is considerable and influenced by disease stage. As aNSCLC patients respond to new treatments and live longer, the societal impact remains to be characterized and more research should be conducted to fill this knowledge gap.

Conference/Value in Health Info

2022-05, ISPOR 2022, Washington, DC, USA

Value in Health, Volume 25, Issue 6, S1 (June 2022)

Code

EE409

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis, Trial-Based Economic Evaluation, Work & Home Productivity - Indirect Costs

Disease

Biologics and Biosimilars, Drugs, Respiratory-Related Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×